What can we do to preserve the peritoneum?

Peritoneal Dialysis International

Volumn 23, Issue SUPPL. 2, 2003, Pages

  Krediet, Raymond T ^a   Zweers, Machteld M ^a   van Westrhenen, Roos ^a   Ho dac Pannekeet, Marja M ^a   Struijk, Dirk G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Biocompatibility; Dialysis solutions; Peritoneal morphology

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINO ACID; BICARBONATE; BUFFER; DIALYSIS FLUID; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; ICODEXTRIN; LACTIC ACID; OSMOTIC AGENT; PYRUVIC ACID; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; BIOCOMPATIBILITY; BLOOD VESSEL; CONCENTRATION (PARAMETERS); DIALYSATE; HYPOXIA; MEDICAL RESEARCH; MESOTHELIUM CELL; NONHUMAN; PATHOGENESIS; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONEUM; PERITONEUM CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REVIEW; TISSUE PRESERVATION; ULTRAFILTRATION;

EID: 0347135875     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080302302s03     Document Type: Review

References (63)

1. Mujais S, Nolph K, Gokal R, Blake P, Burkart J, Coles G, et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20(Suppl 4):S5-21.
2. Ho-dac-Pannekeet MM, Atasever B, Struijk DG, Krediet RT. Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis. Perit Dial Int 1997; 17: 144-50.
3. Heimbürger O, Waniewski J, Werynski A, Tranæus A, Lindholm B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38:495-506.
4. Smit W, Langedijk M, Schouten N, van den Berg N, Struijk D, Krediet R. Analysis of the prevalence and causes of ultrafiltration failure in long-term peritoneal dialysis: a cross sectional study (Abstract). Perit Dial Int 2002; 22:117.
5. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
6. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12:14-27.
7. Mateijsen MA, van der Wal AC, Hendriks PM, Zweers MM, Mulder J, Struijk DG, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19: 517-25.
8. Honda K, Nitta K, Horita H, Yumura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996; 72:171-6.
9. Gotloib L, Bar-Sella P, Shostak A. Reduplicated basal lamina of small venules and mesothelium of human parietal peritoneum. Perit Dial Bull 1985; 5:212-15.
10. Di Paolo N, Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy. Perit Dial Int 1989; 9:41-5.
11. Dobbie JW, Anderson JD, Hind C. Long-term effects of peritoneal dialysis on peritoneal morphology. Perit Dial Int 1994; 14(Suppl 3):S16-20.
12. Hendriks PM, Ho-dac-Pannekeet MM, van Gulik TM, Struijk DG, Phoa SS, Sie L, et al. Peritoneal sclerosis in chronic peritoneal dialysis patients: analysis of clinical presentation, risk factors, and peritoneal transport kinetics. Perit Dial Int 1997; 17:136-43.
13. Koopmans JG, Boeschoten EW, Pannekeet MM, Betjes MG, Zemel D, Kuijper EJ, et al. Impaired initial cell reaction in CAPD-related peritonitis. Perit Dial Int 1996; 16(Suppl 1):S362-7.
14. Topley N, Coles GA, Williams JD. Biocompatibility studies on peritoneal cells. Perit Dial Int 1994; 14(Suppl 3): S21-8.
15. Pedersen FB, Ryttov N, Deleuran P, Dragsholt C, Kildeberg P. Acetate versus lactate in peritoneal dialysis solutions. Nephron 1985; 39:55-8.
16. Breborowicz A, Rodela H, Oreopoulos DG. Toxicity of osmotic solutes on human mesothelial cells in vitro. Kidney Int 1992; 41:1280-5.
17. Gotloib L, Wajsbrot V, Shostak A, Kushnier R. Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose enriched, lactate buffered dialysis solution. Nephron 1995; 70:466-77.
18. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
19. Zweers MM, Splint LJ, Krediet RT, Struijk DG. Ultrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat. Nephrol Dial Transplant 2001; 16:651-4.
20. Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT. Growth factors VEGF and TGF-β1 in peritoneal dialysis. J Lab Clin Med 1999; 134:124-32.
21. Zweers MM, Struijk DG, Smit W, Krediet RT. Vascular endothelial growth factor in peritoneal dialysis. A longitudinal follow-up. J Lab Clin Med 2001; 137:125-32.
22. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12:1046-51.
23. Wieslander AP, Andrén AHG, Nilsson-Thorell C, Muscalu N, Kjellstrand PTT, Rippe B. Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro? Perit Dial Int 1995; 15:348-52.
24. Mahiout A, Brunkhorst R. Pyruvate anions neutralize peritoneal dialysate toxicity. Nephrol Dial Ransplant 1995; 10:391-4.
25. Shostak A, Gotloib L, Kushnier R, Wajsbrot V. Protective effect of pyruvate upon cultured mesothelial cells exposed to 2 mM hydrogen peroxide. Nephron 2000; 4:362-6.
26. Beyer-Mears A, Diecke FP, Mistry K, Ellison C, Cruz E. Effect of pyruvate on lens myo-inositol transport and polyol formation in diabetic cataract. Pharmacology 1997; 55:78-86.
27. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146:1029-39.
28. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42:801-13.
29. Tilton RG, Kawamura T, Chang KC, Ido Y, Bjercke RJ, Stephan CC, et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 1997; 99: 2192-202.
30. Krediet RT, Zemel D, Imholz ALT, Koomen GC, Struijk DG, Arisz L. Indices of peritoneal permeability. Perit Dial Int 1993; 13(Suppl 2):S31-4.
31. Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 2001; 21:560-7.
32. Lai KN, Szeto CC, Lai KB, Lam CWK, Chan BTM, Leung JCK. Increased production of hyaluronan by peritoneal cells and its significance in patients on CAPD. Am J Kidney Dis 1999; 33:318-24.
33. Yamagata K, Tomida C, Koyama A. Intraperitoneal hyaluronan production in stable continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999; 19:131-7.
34. Ho-dac-Pannekeet MM, Krediet RT. Inflammatory changes in vivo during CAPD: what can the effluent tell us? Kidney Int 1996; 50(Suppl 56):S12-16.
35. Zemel D, Imholz ALT, de Waart DR, Dinkla C, Struijk DG, Krediet RT. Appearance of tumor necrosis factor-α and soluble TNF-receptors I and II in peritoneal fluid of CAPD. Kidney Int 1994; 46:1422-30.
36. de Waart DR, Zweers MM, Struijk DG, Krediet RT. Icodextrin degradation products in spent dialysate of CAPD patients and the rat, and its relation with dialysate osmolality. Perit Dial Int 2001; 21:269-74.
37. Lameire N, Van Biesen W, Van Landschoot M, Wang T, Heimbürger O, Bergström J, et al. Experimental models in peritoneal dialysis: a European experience. Kidney Int 1998; 54:2194-206.
38. Zweers MM, de Waart DR, van der Wal AC, Dekker FW, Krediet RT, Struijk DG. Structural and functional changes of the peritoneum in a chronic peritoneal infusion model in the rat. In: Zweers MM. Experimental and Clinical Studies on Peritoneal Physiology and Morphology During Chronic Peritoneal Dialysis (Thesis). Amsterdam: University of Amsterdam; 2000: 77-96.
39. Vrtovsnik F, Zweers MM, de Waart DR, Struijk DG, Krediet RT. Effects of uremia and chronic peritoneal infusion on peritoneal morphology and transport in the rat (Abstract). J Am Soc Nephrol 2001; 12:316A.
40. Miranda O, Selgas R, Celadilla O, Mañoz J, Sanchez-Sicilia L. Peritoneal resting and heparinization as an effective treatment for ultrafiltration failure in patients on CAPD. Contrib Nephrol 1991; 89:199-204.
41. de Alvaro F, Castro MJ, Dapena F, Bajo MA, Fernandez-Reyes MJ, Romero JR, et al. Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure. Adv Perit Dial 1993; 9:56-61.
42. Rodrigues A, Cabrita A, Maia P, Guimarães S. Peritoneal rest may successfully recover ultrafiltration failure. Adv Perit Dial 2002; 18:78-80.
43. Kim YL, Kim SH, Kim JH, Kim SJ, Kim CD, Cho DK, et al. Effects of peritoneal rest on peritoneal transport and peritoneal membrane thickening in continuous ambulatory peritoneal dialysis rats. Perit Dial Int 1999; 19(Suppl 2):S384-7.
44. Burkart J, Stallard R. Results of peritoneal membrane (PM) resting (R) on dialysate (d) CA125 levels and PET results (Abstract). Perit Dial Int 1997; 17(Suppl 1):S5.
45. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT. Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int 1997; 51:888-93.
46. Ho-dac-Pannekeet MM, de Waart DR, Hiralall JK, Struijk DG, Krediet RT. A comparison between glucose and glycerol based dialysis solutions during the first six months of peritoneal dialysis. In: Ho-dac-Pannekeet MM. Assessment of Peritoneal Permeability and Mesothelial Cell Mass in Peritoneal Dialysis Patients (Thesis). Amsterdam: University of Amsterdam; 1997: 227-55.
47. Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
48. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranæus A, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529-38.
49. Craig KJ, Mackenzie RK, Lage C, Williams JD, Schaub T, Passlick-Deetjen J, et al. Treatment with low GDP solution (Balance) is associated with an increase in effluent CA125 and a decrease in HA content: data from the multi-centre Euro-Balance trail (Abstract). Perit Dial Int 2002; 22(Supp1 2):S21.
50. van Westrhenen R, Zweers MM, Kunne C, de Waart DR, Krediet RT. Prevention of pseudohypoxia by pyruvate in a chronic peritoneal exposure model in the rat (Abstract). Perit Dial Int 2002; 22:105.
51. Bazzato G, Fracasso A, Gambaro G, Baggio B. Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis. Lancet 1995; 346:740-1.
52. Zweers M, Struijk DG, Krediet RT. Effects of IP dalteparin in long-term PD patients (Abstract). Perit Dial Int 2000; 20:156.
53. Breborowicz A, Wieczorowska K, Martis L, Oreopoulos DG. Glycosaminoglycan chondroitin sulphate prevents loss of ultrafiltration during peritoneal dialysis in rats. Nephron 1994; 67:346-50.
54. Wang T, Chen C, Heimbürger O, Waniewski J, Bergström J, Lindholm B. Hyaluronan decreases peritoneal fluid absorption in peritoneal dialysis. J Am Soc Nephrol 1997; 8:1915-20.
55. Wang T, Cheng HH, Heimbürger O, Waniewski J, Bergström J, Lindholm B. Hyaluronan prevents the decreased net ultrafiltration caused by increased peritoneal dialysate fill volume. Kidney Int 1998; 53: 496-502.
56. Polubinska A, Pawlaczyk K, Küzlan-Pawlaczyk M, Wieczorowska-Tobis K, Chen C, Moberly JB, et al. Dialysis solution containing hyaluronan: effect on peritoneal permeability and inflammation in rats. Kidney Int 2000; 57:1182-9.
57. Di Paolo N, Buoncristiani U, Capotondo L, Gaggiotti E, De Mia M, Rossi P, et al. Phosphatidylcholine and peritoneal transport during peritoneal dialysis. Nephron 1986; 44:365-70.
58. Dombros N, Balaskas E, Savidis N, Tourkantonis A, Sombolos K. Phosphatidylcholine increases ultrafiltration in continuous ambulatory peritoneal dialysis patients. In: Avram MM, Giondano C, eds. Ambulatory Peritoneal Dialysis. New York: Plenum; 1990: 39-41.
59. Querques M, Procaccini DA, Pappani A, Srippoli P, Passione A. Influence of phosphatidylcholine on ultrafiltration and solute transfer in CAPD patients. ASAIO Trans 1990; 36:M581-3.
60. Krack G, Viglino G, Cavalli PL, Gandolfo C, Magliano G, Cantaluppi A, et al. Intraperitoneal administration of phosphatidylcholine improves ultrafiltration in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1992; 12:359-64.
61. Struijk DG, van der Reijden HJ, Krediet RT, Koomen GC, Arisz L. Effect of phosphatidylcholine on peritoneal transport and lymphatic absorption in a CAPD patient with sclerosing peritonitis. Nephron 1989; 51: 577-8.
62. Mactier RA, Khanna R, Twardowski ZJ, Moore H, Nolph KDA. Influence of phosphatidylcholine on lymphatic absorption during peritoneal dialysis in the rat. Perit Dial Int 1988; 8:179-86.
63. De Vecchi A, Castelnovo C, Guerra L, Scalamogna A. Phosphatidylcholine administration in continuous ambulatory peritoneal dialysis (CAPD) patients with reduced ultrafiltration. Perit Dial Int 1989; 9:207-10.